Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS) : an urgent need for treatment management
Copyright © 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved..
INTRODUCTION: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease that affects mainly adults between 50 and 55 years. In Brazil, information from the Sistema Único de Saúde (SUS) Outpatient Information System indicates that 12,531 patients had the Autorização de Procedimento Ambulatorial (APAC) approved for the CML treatment in 2017. Disease monitoring through molecular response evaluation is critical to the care of CML patients. The quantitative PCR test (real-time polymerase chain reaction) provides adequate evaluation parameters that allow the health professional to intervene at the right moments in order to reduce the chance of progression of the disease, providing the best outcome to the patient, including the possibility of treatment discontinuation for eligible patients. Although the test is included in the Clinical Protocol and Therapeutic Guidelines (PCDT) of CML, it is not possible to monitor the molecular response within SUS since there is no reimbursement for this test.
OBJECTIVE: Obtain expert recommendations on the importance, financing, and reimbursement of molecular monitoring in SUS.
METHODS: Six CML experts with different perspectives participated in the panel. The discussion was based in the main publications about the quantitative PCR test in CML monitoring.
RESULTS: Experts' recommendations: CONCLUSION: A solution for the molecular test (BCR-ABL1) funding is urgent to ensure the monitoring of CML patients in SUS. The savings that might be generated with patients that stop taking the medication when adequately monitored may finance the test.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Hematology, transfusion and cell therapy - 43(2021), 1 vom: 28. Jan., Seite 50-57 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boquimpani, Carla Maria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BCR-ABL |
|---|
| Anmerkungen: |
Date Revised 06.03.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.htct.2020.02.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310562260 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310562260 | ||
| 003 | DE-627 | ||
| 005 | 20231225140352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.htct.2020.02.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310562260 | ||
| 035 | |a (NLM)32475788 | ||
| 035 | |a (PII)S2531-1379(20)30055-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boquimpani, Carla Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS) |b an urgent need for treatment management |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved. | ||
| 520 | |a INTRODUCTION: Chronic Myeloid Leukemia (CML) is a myeloproliferative disease that affects mainly adults between 50 and 55 years. In Brazil, information from the Sistema Único de Saúde (SUS) Outpatient Information System indicates that 12,531 patients had the Autorização de Procedimento Ambulatorial (APAC) approved for the CML treatment in 2017. Disease monitoring through molecular response evaluation is critical to the care of CML patients. The quantitative PCR test (real-time polymerase chain reaction) provides adequate evaluation parameters that allow the health professional to intervene at the right moments in order to reduce the chance of progression of the disease, providing the best outcome to the patient, including the possibility of treatment discontinuation for eligible patients. Although the test is included in the Clinical Protocol and Therapeutic Guidelines (PCDT) of CML, it is not possible to monitor the molecular response within SUS since there is no reimbursement for this test | ||
| 520 | |a OBJECTIVE: Obtain expert recommendations on the importance, financing, and reimbursement of molecular monitoring in SUS | ||
| 520 | |a METHODS: Six CML experts with different perspectives participated in the panel. The discussion was based in the main publications about the quantitative PCR test in CML monitoring | ||
| 520 | |a RESULTS: Experts' recommendations: CONCLUSION: A solution for the molecular test (BCR-ABL1) funding is urgent to ensure the monitoring of CML patients in SUS. The savings that might be generated with patients that stop taking the medication when adequately monitored may finance the test | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BCR-ABL | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a PCR | |
| 650 | 4 | |a Quantitative real-time | |
| 650 | 4 | |a Reimbursement mechanisms | |
| 700 | 1 | |a Abdo, André Neder Ramires |e verfasserin |4 aut | |
| 700 | 1 | |a Martins, Denise Pires |e verfasserin |4 aut | |
| 700 | 1 | |a Lima, Luciana Britto de Abreu |e verfasserin |4 aut | |
| 700 | 1 | |a Torriani, Mayde Seadi |e verfasserin |4 aut | |
| 700 | 1 | |a Bendit, Israel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hematology, transfusion and cell therapy |d 2018 |g 43(2021), 1 vom: 28. Jan., Seite 50-57 |w (DE-627)NLM286978962 |x 2531-1387 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2021 |g number:1 |g day:28 |g month:01 |g pages:50-57 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.htct.2020.02.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2021 |e 1 |b 28 |c 01 |h 50-57 | ||